

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.nspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/780,612	02/12/2001	Janardan Kumar	1579-434	9116
23117	7590 06/17/2003			
	ANDERHYE, PC	EXAMINER		
1100 N GLEB 8TH FLOOR	E ROAD		HADDAD, N	MAHER M
ARLINGTON	, VA 22201-4714		ART UNIT	PAPER NUMBER
			1644	7.4
			DATE MAILED: 06/17/2003	11

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
		09/780,612	KUMAR ET AL.
	Office Action Summary	Examiner	Art Unit
		Maher M. Haddad	1644
Period fo	The MAILING DATE of this communication ap or Reply	pears on the cover shee	t with the correspondence address
THE N - Exter after - If the - If NO - Failur - Any r	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reprepriod for reply is specified above, the maximum statutory period to to reply within the set or extended period for reply will, by statutely received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, ma ly within the statutory minimum o will apply and will expire SIX (6) e, cause the application to becom	y a reply be timely filed  f thirty (30) days will be considered timely.  MONTHS from the mailing date of this communication.  e ABANDONED (35 U.S.C. § 133).
1)🖂	Responsive to communication(s) filed on 04	December 2002 .	
2a)□	This action is <b>FINAL</b> . 2b) ☐ Th	nis action is non-final.	•
3)□ Dispositi	Since this application is in condition for allow closed in accordance with the practice under on of Claims	•	· ·
4)🛛	Claim(s) $1-12$ is/are pending in the application	า.	
	4a) Of the above claim(s) is/are withdra	wn from consideration.	
5)□	Claim(s) is/are allowed.		
6)□	Claim(s) is/are rejected.		
7)	Claim(s) is/are objected to.	•	
8)🖂	Claim(s) 1-12 are subject to restriction and/or	election requirement.	
Applicati	on Papers		
9) 🗌 🧻	The specification is objected to by the Examine	er.	
10)[] 7	Γhe drawing(s) filed on is/are: a)□ acce	pted or b) objected to b	by the Examiner.
	Applicant may not request that any objection to the		
11)[] 7	The proposed drawing correction filed on	_ is: a)□ approved b)□	disapproved by the Examiner.
_	If approved, corrected drawings are required in re	ply to this Office action.	
12)[_] 7	The oath or declaration is objected to by the Ex	caminer.	
Priority u	nder 35 U.S.C. §§ 119 and 120		
13)	Acknowledgment is made of a claim for foreign	n priority under 35 U.S.	C. § 119(a)-(d) or (f).
a)[	☐ All b)☐ Some * c)☐ None of:		
	1. Certified copies of the priority document	s have been received.	
	<ol><li>Certified copies of the priority document</li></ol>	s have been received in	Application No
	<ol> <li>Copies of the certified copies of the prio application from the International Bute the attached detailed Office action for a list</li> </ol>	reau (PCT Rule 17.2(a	)).
	cknowledgment is made of a claim for domest	•	
_a)	The translation of the foreign language procedures to the control of the control	ovisional application has	s been received.
Attachment	-	-	•
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Notice	ew Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)
S. Patent and Tra TO-326 (Rev		ction Summary	Part of Paper No. 11

Application/Control Number: 09/780,612

Art Unit: 1644

## DETAILED ACTION Restriction Requirement

1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 1-8, drawn to a method of treating a mammal having a disease of the eye characterized by elevated intraocular pressure comprising administering a compound wherein the compound comprises the <u>peptide RGD or derivative thereof</u>, classified in Class 514, subclass 17.
- II. Claims 1-3 and 6-8, drawn to a method of treating a mammal having a disease of the eye characterized by elevated intraocular pressure comprising administering a compound wherein the compound comprises the peptide <u>RGD mimetic</u> thereof, classified in Class 514, subclass 17.
- III. Claim 9, drawn to a method of screening a test compound for its ability to inhibit an interaction between integrin and extracellular matrix comprising contacting juxacanalicular or Schlemm's canal cells with an <u>extracellular matrix</u>; classified in Class 435, subclass 7.1.
- IV. Claim 10, drawn to drawn to a method of screening a test compound for its ability to inhibit an interaction between integrin and extracellular matrix comprising contacting juxacanalicular or Schlemm's canal cells with <u>a tracer</u>, classified in Class 435, subclass 7.1.
- V. Claim 11, drawn to a compound identifiable using the method comprising contacting juxacanalicular or Schlemm's canal cells with an <u>extracellular matrix</u>, classified in Class 530, subclass 350.
- VI. Claim 12, drawn to a compound identifiable using the method comprising contacting juxacanalicular or Schlemm's canal cells with a <u>tracer</u>, classified in Class 530, subclass 350.
- 2. Groups V and VI are different products. Different test compounds differ with respect to their structures and physicochemical properties; therefore each product is patentably distinct.
- 3. Groups I-IV are different methods. Methods of treating and methods of screening differ with respect to ingredients (i.e. peptide RGD or derivative thereof in Group I, RGD mimetic in Group II, an extracellular matrix in Group III and a tracer in Group IV), method steps, and endpoints; therefore, each method is patentably distinct.

Art Unit: 1644

- 4. These inventions are distinct for the reasons given above. In addition, they have acquired a separate status in the art as shown by different classification and/or recognized divergent subject matter. Further, even though in some cases the classification is shared, a different field of search would be required based upon the structurally distinct products recited and the various methods of use comprising distinct method steps. Therefore restriction for examination purposes as indicated is proper.
- 5. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 6. A telephone call was made to Mary J. Wilson on 6/4/03 to request an oral election to the above restriction requirement, but did not result in an election being made. A written restriction was requested.
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maher Haddad whose telephone number is (703) 306-3472. The examiner can normally be reached Monday through Friday from 8:00 AM to 4:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Maher Haddad, Ph.D. Patent Examiner Technology Center 1600 June 16, 2003

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600